250 related articles for article (PubMed ID: 33522247)
1. Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
Zhao J; Jiang X; Liu J; Ye P; Jiang L; Chen M; Xia J
J Am Heart Assoc; 2021 Feb; 10(4):e014311. PubMed ID: 33522247
[TBL] [Abstract][Full Text] [Related]
2. Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression.
Ye P; Liu J; Xu W; Liu D; Ding X; Le S; Zhang H; Chen S; Chen M; Xia J
Hepatology; 2019 May; 69(5):1946-1964. PubMed ID: 30582764
[TBL] [Abstract][Full Text] [Related]
3. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Li CY; Zhou Q; Yang LC; Chen YH; Hou JW; Guo K; Wang YP; Li YG
Basic Res Cardiol; 2016 Mar; 111(2):19. PubMed ID: 26891723
[TBL] [Abstract][Full Text] [Related]
4. Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload.
Li WM; Zhao YF; Zhu GF; Peng WH; Zhu MY; Yu XJ; Chen W; Xu DC; Xu YW
Clin Sci (Lond); 2017 Jan; 131(2):141-154. PubMed ID: 27702885
[TBL] [Abstract][Full Text] [Related]
5. C1q-tumour necrosis factor-related protein-3 exacerbates cardiac hypertrophy in mice.
Ma ZG; Yuan YP; Zhang X; Xu SC; Kong CY; Song P; Li N; Tang QZ
Cardiovasc Res; 2019 May; 115(6):1067-1077. PubMed ID: 30407523
[TBL] [Abstract][Full Text] [Related]
6. Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.
Chen L; Huang J; Ji YX; Mei F; Wang PX; Deng KQ; Jiang X; Ma G; Li H
Hypertension; 2017 Feb; 69(2):249-258. PubMed ID: 27956576
[TBL] [Abstract][Full Text] [Related]
7. SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1-Dependent Manner.
Qian Q; Hu F; Yu W; Leng D; Li Y; Shi H; Deng D; Ding K; Liang C; Liu J
J Am Heart Assoc; 2023 Apr; 12(7):e028628. PubMed ID: 36974751
[TBL] [Abstract][Full Text] [Related]
8. Dual-specificity phosphatase 26 protects against kidney injury caused by ischaemia-reperfusion through restraint of TAK1-JNK/p38-mediated apoptosis and inflammation of renal tubular epithelial cells.
Xiang H; Li Z; Li Y; Zheng J; Dou M; Xue W; Wu X
Toxicol Appl Pharmacol; 2024 Jun; 487():116954. PubMed ID: 38705402
[TBL] [Abstract][Full Text] [Related]
9. Regulator of G Protein Signaling 6 Facilities Cardiac Hypertrophy by Activating Apoptosis Signal-Regulating Kinase 1-P38/c-JUN N-Terminal Kinase 1/2 Signaling.
Huang Z; Shu J; Jiang W; Jiang M; Lu Y; Dai H; Xu N; Yuan H; Cai J
J Am Heart Assoc; 2018 Oct; 7(19):e009179. PubMed ID: 30371330
[TBL] [Abstract][Full Text] [Related]
10. DUSP26 regulates podocyte oxidative stress and fibrosis in a mouse model with diabetic nephropathy through the mediation of ROS.
Huang F; Sheng XX; Zhang HJ
Biochem Biophys Res Commun; 2019 Jul; 515(3):410-416. PubMed ID: 31155289
[TBL] [Abstract][Full Text] [Related]
11. Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy.
Gao L; Huang K; Jiang DS; Liu X; Huang D; Li H; Zhang XD; Huang K
Hypertension; 2015 Apr; 65(4):871-81. PubMed ID: 25646292
[TBL] [Abstract][Full Text] [Related]
12. Novel Protective Role for Ubiquitin-Specific Protease 18 in Pathological Cardiac Remodeling.
Ying X; Zhao Y; Yao T; Yuan A; Xu L; Gao L; Ding S; Ding H; Pu J; He B
Hypertension; 2016 Nov; 68(5):1160-1170. PubMed ID: 27572150
[TBL] [Abstract][Full Text] [Related]
13. Dual-specificity phosphatase 26 (DUSP26) stimulates Aβ42 generation by promoting amyloid precursor protein axonal transport during hypoxia.
Jung S; Nah J; Han J; Choi SG; Kim H; Park J; Pyo HK; Jung YK
J Neurochem; 2016 Jun; 137(5):770-81. PubMed ID: 26924229
[TBL] [Abstract][Full Text] [Related]
14. ADAM23 in Cardiomyocyte Inhibits Cardiac Hypertrophy by Targeting FAK - AKT Signaling.
Xiang M; Luo H; Wu J; Ren L; Ding X; Wu C; Chen J; Chen S; Zhang H; Yu L; Zou Y; Xu H; Ye P; Chen M; Xia J
J Am Heart Assoc; 2018 Sep; 7(18):e008604. PubMed ID: 30371220
[TBL] [Abstract][Full Text] [Related]
15. FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway.
Hui X; Hu F; Liu J; Li C; Yang Y; Shu S; Liu P; Wang F; Li S
J Mol Cell Cardiol; 2021 Feb; 151():31-43. PubMed ID: 32971071
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
[TBL] [Abstract][Full Text] [Related]
17. Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.
Li L; Chen W; Zhu Y; Wang X; Jiang DS; Huang F; Wang L; Xiang F; Qin W; Wang Q; Zhang R; Zhu X; Li H; Chen X
Hypertension; 2014 Jul; 64(1):94-102. PubMed ID: 24777975
[TBL] [Abstract][Full Text] [Related]
18. Novel role of mitochondrial GTPases 1 in pathological cardiac hypertrophy.
Xu D; Zhao Y; Weng X; Lu Y; Li W; Tang K; Chen W; Liu Z; Qi X; Zheng J; Fassett J; Zhang Y; Xu Y
J Mol Cell Cardiol; 2019 Mar; 128():105-116. PubMed ID: 30707992
[TBL] [Abstract][Full Text] [Related]
19. Sialyltransferase7A promotes angiotensin II-induced cardiomyocyte hypertrophy via HIF-1α-TAK1 signalling pathway.
Yan X; Zhao R; Feng X; Mu J; Li Y; Chen Y; Li C; Yao Q; Cai L; Jin L; Han C; Zhang D
Cardiovasc Res; 2020 Jan; 116(1):114-126. PubMed ID: 30854566
[TBL] [Abstract][Full Text] [Related]
20. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
